The Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.) is delighted to welcome Sandra Putney to the foundation’s Board of Directors, where she will assume the duties of Treasurer. Sandra is committed to using her business acumen and leadership abilities to safeguard donor dollars while ensuring that donations are maximized for the organization’s mission.
Scientists have identified a novel therapeutic approach for the most frequent genetic cause of Amyotrophic lateral sclerosis (ALS).
The R.A.S.C.A.L.S. would like to acknowledge Greg Regan, who stepped down earlier this year from his post as Treasurer for the foundation. A member of the organization’s inaugural Board of Directors, Greg was instrumental in helping lay the groundwork for this charity’s signature events and educational efforts.
My heartfelt thanks goes out to all of you who helped to make the R.A.S.C.A.L.S. Second Annual 5K Walk/Run a resounding success.
2013 RASCALS 5K Official Results by Age Group and Overall Rankings.
AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.
The research is based around the importance of a protein called Brain-Derived Neurotropic Factor (BDFN) in the development of pathology. BDFN is produced in both neurons and muscles, carrying signals between those two parts of the motor unit—communication that is critical to proper functioning of the muscle, Ottem said.
Please join the Robert A. Stehlin Campaign for ALS (RASCALS) to “Fight ALS One Step At A Time”
on Saturday, Nov. 2nd, Tower Grove Park.
“In these studies, we turned skin cells of patients who have ALS into motor neurons that retained the genetic defects of the disease,” Baloh said. “We focused on a gene, C9ORF72, that two years ago was found to be the most common cause of familial ALS and frontotemporal lobar degeneration, and even causes some cases of Alzheimer’s and Parkinson’s disease. What we needed to know, however, was how the defect triggered the disease so we could find a way to treat it.”
“We’re trying to prime the pump and fund (researchers) before they go into clinical trials,” said Melissa Forsythe, director of the Pentagon’s ALS Research Program. “Our goal every year is to make the very best investment we can.”